Skip to content
Erudio Health
menu
Oncology · For Medical Affairs

What clinicians say about clinical trials, and why.

How oncologists read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question. Every view links to its source. Read the two-minute summary yourself, or let your AI agent work through the evidence.

Explore the report previews

View for
Try: · · ·
Report size
TrialSizePreview
QUINTESSENTIAL-2Free
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
StandardPreview
CheckMate 744
NCT02927769 · Bristol-Myers Squibb
StandardPreview
PROUD-PV
NCT01949805 · AOP Orphan Pharmaceuticals AG
DeepPreview
NEONIPIGA
NCT04006262 · GERCOR - Multidisciplinary Oncology Cooperative Group
DeepPreview
CALGB-10403
NCT00558519 · Alliance for Clinical Trials in Oncology
DeepPreview
MARS2
NCT02040272 · Royal Brompton & Harefield NHS Foundation Trust
DeepPreview
EURTAC
NCT00446225 · Spanish Lung Cancer Group
StandardPreview
SURTIME
NCT01099423 · European Organisation for Research and Treatment of Cancer - EORTC
DeepPreview
MSLT-II
NCT00297895 · Saint John's Cancer Institute
DeepPreview
EA3191
NCT04671667 · National Cancer Institute (NCI)
FocusedPreview

10 of 10 reports

  • 10 published reports
  • any listed oncology trial built within 24 hours
  • weekly updates
  • every statement source-linked
all reports and trials →
What you get

One trial, read three ways.

Every report has the same three parts, for you, for the colleagues you forward it to, and for your AI agent.

For you and your VP

Executive summary

The two-minute read: how the clinicians who discussed the trial read it, where they differ, and the open question for Medical Affairs. A PDF to forward.

For your Medical Directors

Detailed analysis

The reasoning, disagreements, qualifications and counterviews behind each finding, to read in your browser.

For your AI agent

Structured evidence

Every verified HCP statement with its speaker, date, short quote and link, as JSON and through the Erudio MCP, so your agent can check any finding.

Follow a trial with weekly updates: when the commentary changes a finding you get a new edition and a note of what changed, and when nothing changes you get a dated note that the report is current.

Free report · QUINTESSENTIAL-2

Check our work before you buy.

The open question for Medical Affairs

What comparative benefit would distinguish target diversification from a clinically meaningful improvement over the trial's standard-care options?

  1. 01An attractive non-BCMA option, with superiority still an open question
  2. 02Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal
  3. 03Post-BCMA placement is attractive, but antigen switching is not an automatic rule
  4. 04Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure

The complete QUINTESSENTIAL-2 report is free: the executive summary, the analysis of every finding, and the verified HCP statements behind them, each linked to the podcast, video or post it came from. Trace any finding to its source.

227 verified HCP statements from 8 commentary sources · 9 findings · updated Oct 9, 2026

How it compares

What you have today, and what Erudio adds.

Most teams already pay for some of these. Erudio fills the gap between them: the clinician's own reasoning about a trial, in public, with the source.

You haveIt gives youErudio adds
KOL and HCP databasesWho a clinician is: affiliations, publications, trials.What they said about a trial, where and when, with their reasoning. Use both.
Social listeningMentions and sentiment, mostly from short posts.Long-form podcasts and video as well as X, with clinical views kept apart from reactions.
Field medical insightsWhat your MSLs heard in private conversations.What clinicians say in public, with optional NPI and ORCID linkages to connect each voice to your expert records in Salesforce, Veeva or other NPI-keyed systems. It complements your field insights and never ingests them.
Agencies and congress reportsOne question per project, in weeks.A report on any listed trial within 24 hours, with every source linked, plus weekly updates.
General AI chatFast answers with uncertain sources.Every statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps.
Two products

Every report works with your agent. Enterprise adds the whole corpus.

Reports

One trial, one report, agent included

What clinicians said about a trial in podcasts, videos and posts, why their readings differ, and the source behind every view: an executive summary to forward, the analysis, and the evidence your AI agent can query, with no enterprise contract. Buy the current edition, or follow a trial with 3, 6 or 12 months of weekly updates. Trials without a report are built within 24 hours of your order.

Enterprise MCP

The whole corpus, for your agents

Search across all the HCP podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses, from Microsoft Copilot, ChatGPT, Claude or your own agent. Ask “prep me for my meetings with these five oncologists” and get sourced answers.

Method

How a report is built

Every report separates what clinicians said from what the primary evidence establishes. We never turn commentary into an efficacy verdict or a consensus.

  1. 01

    Resolve the trial

    One registry record, its aliases, no look-alikes

  2. 02

    Gather sources

    Podcasts, videos and X posts that name the trial

  3. 03

    Screen and extract

    Each view, question and reason becomes a statement

  4. 04

    Audit

    Every statement checked against its original passage

  5. 05

    Compose

    What clinicians said and why, beside the primary facts

  6. 06

    Review

    Findings checked for fidelity and overclaiming

  7. 07

    Version and publish

    A hashed, versioned edition with a changelog

  8. Read the methods →
Use cases

Built around the jobs Medical Affairs already does.

Trust

Public sources only. Every statement linked. Every edition versioned, with corrections in the open.

  • Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
  • Co-founder Audun Utengen has published research with clinicians in BMJ, JAMA Oncology and the European Heart Journal
  • Erudio Health has received a Security-only SOC 2 Type II report, available under NDA
  • Reports state what they do not cover, on every page
  • Non-promotional: no efficacy verdicts, consensus scores or rankings. Trust center